U.S. drug regulators are investigating whether the cholesterol-lowering drug Vytorin might be linked to cancer. The U.S. Food and Drug Administration informed health care professionals that the agency was investigating a report of a possible association between the use of Vytorin and an increased risk of a variety of cancers. The FDA said it expects to receive a final report from the group conducting the study later this month. In the meantime, the FDA advises health care professionals to monitor patients taking Vytorin for possible side effects.
Vytorin is made by the drug companies Merck and Schering-Plough Pharmaceuticals. To read the full story, click here.